Leukocytoclastic vasculitis induced by low-dose methotrexate: In vitro evidence for an immunologic mechanism

Journal of the European Academy of Dermatology and Venereology

Volumn 10, Issue 1, 1998, Pages 81-85

  Halevy, Sima ^a   Giryes, Hani ^a   Avinoach, Ilana ^a   Livni, Ella ^b   Sukenik, Shaul ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Leukocytoclastic vasculitis; Mast cell degranulation test; Methotrexate

Indexed keywords

METHOTREXATE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; FEMALE; HUMAN; LEUKOCYTOCLASTIC VASCULITIS; MAST CELL DEGRANULATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELL DEGRANULATION; DRUG HYPERSENSITIVITY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; MAST CELLS; METHOTREXATE; SKIN DISEASES, VASCULAR; VASCULITIS, HYPERSENSITIVITY;

EID: 0031907326     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0926-9959(97)00114-1     Document Type: Article

References (23)

1. Reynolds JEF, ed. Martindale - The Extra Pharmacopoeia, 29th edn. London: The Pharmaceutic Press, 1989;636.
2. Lanzkowsky P, Jayabose S, Shende A, Levy R. Vasculitis as a complication of high-dose methotrexate in the treatment of acute leukemia (letter). Am J Dis Child 1976;130:675.
3. Marks CR, Willkens RF, Wilske KR, Brown PB. Small-vessel vasculitis and methotrexate (letter). Ann Intern Med 1984;100:916.
4. Navarro M, Pedragosa R, Lafuerza A, Rubio D, Huguet P. Leucocytoclastic vasculitis after high-dose methotrexate (letter). Ann Intern Med 1986;105:471-472.
5. Fonndeviila CG, Milone GA, Pavlovsky S. Cutaneous vasculitis after intermediate dose of methotrexate (IDMTX). Br J Haem 1989;72:591-592.
6. Schwartz J, Klopstock A, Zikert-Duvdevani P, Honig S. Detection of hypersensitivity by indirect mast cell degranulation. Int Arch Allergy 1965;26:333-339.
7. Livni E, Halevy S, Sthal B, Joshua H. The appearance of macrophage migration inhibition factor in drug reactions. J Allergy Clin Immunol 1987;80:843-849.
8. Weiss RB. Hypersensitivity reactions to cancer chemotherapy. Semin Oncol 1982;9:5-13.
9. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-831.
10. Thishler M, Caspi D, Rosenbach TO, Fishel B, Wigler I, Segal R, Gazit E, Yaron M. Methotrexate in rheumatoid arthritis: a prospective study in Israeli patients with immunogenetic correlations. Ann Rheum Dis 1988;47:654-659.
11. Segal R, Caspi D, Tishler M, Fishel B, Yaron M. Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1980;31:1182-1185.
12. Hurd ER. Immunosuppressive and antiinflammatory properties of cyclophosphamide, azathioprine, and methotrexate. Arthritis Rheum 1973;16:84-88.
13. Sperling RI, Benincaso AI, Andersen RJ, Coblyn JS, Austen KF, Weinblatt ME. Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 1992;35:376-384.
14. Mota I, Silva WD. Antigen-induced damage to isolated sensitized mast cells. Nature 1960;186:245-246.
15. Tanay A, Yust I, Brenner S, Koffler M, Abramov AL. Dermal vasculitis due to coumadin hypersensitivity. Dermatologica 1982;165:178-185.
16. Halevy S, Ingber A, Feuerman EJ. Subcorneal pustular dermatosis - an unusual course. Acta Derm Venereol (Stockh) 1983;63:441-444.
17. Grunwald MH, Halevy S, Livni E. Allergic vasculitis induced by hydrochlorothiazide: confirmation by mast cell degranulation test. Isr J Med Sci 1989;25:572-574.
18. Amichai B, Grunwald MH, Livni E, Halevy S. Photosensitivity due to isotretinoin: a possible allergic mechanism. J Eur Acad Dermatol Venereol 1993;2:27-30.
19. Ruzicka AT, Ring I, Braun-Falco O. Vasculitis allergica Durch Vitamin B6. Hautartz 1984;35:197-199.
20. Bork K. Cutaneous Side-Effects of Drugs. Philadelphia: WB Saunders, 1988;400.
21. Brooner AK, Hood AF. Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol 1983;9:645-663.
22. Hood AF. Cutaneous side-effects of cancer chemotherapy. Med Clin North Am 1986;70:187-209.
23. Halevy S, Grunwald MH, Sandbank M, Buimovice B, Josuah H, Livni E. Macrophage migration inhibition factor (MIF) in drug eruption. Arch Dermatol 1990;126:48-51.